Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 403

1.

3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.

Oh SJ, Claussen GG, Hatanaka Y, Morgan MB.

Muscle Nerve. 2009 Nov;40(5):795-800. doi: 10.1002/mus.21422.

PMID:
19722254
2.

A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.

Sanders DB, Massey JM, Sanders LL, Edwards LJ.

Neurology. 2000 Feb 8;54(3):603-7.

PMID:
10680790
3.

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, Titulaer MJ, Tjaden UR, den Hartigh J, van Gerven JM.

Clin Pharmacol Ther. 2009 Jul;86(1):44-8. doi: 10.1038/clpt.2009.35. Epub 2009 Apr 8.

PMID:
19357643
4.

Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.

Quartel A, Turbeville S, Lounsbury D.

Curr Med Res Opin. 2010 Jun;26(6):1363-75. doi: 10.1185/03007991003745209. Review.

PMID:
20377318
5.

Treatment in Lambert-Eaton myasthenic syndrome.

Maddison P.

Ann N Y Acad Sci. 2012 Dec;1275:78-84. doi: 10.1111/j.1749-6632.2012.06769.x. Review.

PMID:
23278581
6.

Treatment for Lambert-Eaton myasthenic syndrome.

Keogh M, Sedehizadeh S, Maddison P.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD003279. doi: 10.1002/14651858.CD003279.pub3. Review.

PMID:
21328260
7.

Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.

Lundh H, Nilsson O, Rosén I, Johansson S.

Acta Neurol Scand. 1993 Aug;88(2):136-40.

PMID:
8213058
9.

3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.

Wirtz PW, Titulaer MJ, Gerven JM, Verschuuren JJ.

Expert Rev Clin Immunol. 2010 Nov;6(6):867-74. doi: 10.1586/eci.10.57. Review.

PMID:
20979551
10.

Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.

Maddison P, Newsom-Davis J, Mills KR.

J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):213-7.

11.

3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.

Molgó J, Guglielmi JM.

Pflugers Arch. 1996;431(6 Suppl 2):R295-6. Review.

PMID:
8739381
12.

3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.

McEvoy KM, Windebank AJ, Daube JR, Low PA.

N Engl J Med. 1989 Dec 7;321(23):1567-71.

PMID:
2555713
13.

[Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].

Jost WH, Mielke U, Forrett-Kaminsky MC, Schimrigk K.

Rev Neurol (Paris). 1992;148(12):776-9. French.

PMID:
1303573
14.

Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome.

Tim RW, Sanders DB.

Muscle Nerve. 1994 Sep;17(9):995-1001.

PMID:
8065402
15.

Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer.

Maddison P, Lang B, Mills K, Newsom-Davis J.

J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):212-7.

16.

Treatment for Lambert-Eaton myasthenic syndrome.

Maddison P, Newsom-Davis J.

Cochrane Database Syst Rev. 2003;(2):CD003279. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD003279.

PMID:
12804456
17.

3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).

Sanders DB.

Ann N Y Acad Sci. 1998 May 13;841:811-6. No abstract available.

PMID:
9668334
18.
19.
20.

Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.

Satoh K, Motomura M, Suzu H, Nakao Y, Fujimoto T, Fukuda T, Nakane S, Nakamura T, Eguchi K.

J Neurol Sci. 2001 Jan 15;183(1):1-4.

PMID:
11166786

Supplemental Content

Support Center